EUDA
EUDA Health Holdings Limited
There isn't enough reported data to score EUDA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
EUDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EUDA's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EUDA PE Valuation
EUDA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EUDA Forward outlook
There aren't enough analyst estimates for EUDA to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EUDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.23 | -$1.11 |
| Q1 2026 | -$2.40 | +$4.40 |
| Q4 2025 | -$2.56 | +$9.92 |
| Q3 2025 | -$1.31 | +$11.43 |
EUDA is still losing money, but far less than before: $2.23 per share over the past year, against $46.80 at its worst in mid-2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EUDA on earnings quality, reporting a profit while its opponent remains loss making.
EUDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.7M | +13% |
| Q1 2026 | $1.7M | +13% |
| Q4 2025 | $6.8M | +549% |
| Q3 2025 | $1.9M | +79% |
| Q2 2025 | $1.5M | +60% |
| Q1 2025 | $1.5M | +60% |
| Q4 2024 | $1.1M | +10% |
| Q2 2024 | $954K | -14% |
EUDA has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -22% | +15 points |
| Q1 2026 | -22% | +15 points |
| Q4 2025 | -36% | +11 points |
| Q3 2025 | -36% | +11 points |
| Q2 2025 | -37% | +820 points |
| Q1 2025 | -37% | +820 points |
| Q4 2024 | -47% | +18 points |
| Q3 2024 | -47% | N/A |
EUDA's operating margin was −22% last quarter, up 15 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EUDA on profitability, with a higher operating margin.
EUDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$603K | +$16.3K |
| Q1 2026 | -$603K | +$16.3K |
| Q4 2025 | -$2.5M | -$2.1M |
| Q3 2025 | -$632.6K | -$196.7K |
| Q2 2025 | -$619.3K | +$10.6K |
| Q1 2025 | -$619.3K | +$10.6K |
| Q4 2024 | -$435.9K | -$65.7K |
| Q2 2024 | -$629.9K | -$629.9K |
EUDA has burned cash in most quarters: −$4M over the past year, against −$2M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over EUDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
EUDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +31% | +572K shares |
| 3 years | +141% | +1.4M shares |
| 5 years | +555% | +2.1M shares |
EUDA has 2M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
EUDA hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EUDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EUDA Net Leverage
EUDA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EUDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.3 | Neutral |
EUDA's weekly RSI is 49 (neutral) and its Stochastic is 42 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EUDA PE vs Healthcare Sector
EUDA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EUDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.1 | 1.9% below |
| 20 week MA | $15.1 | 4.6% above |
| 50 week MA | $19.8 | 20% below |
| 100 week MA | $43.0 | 63% below |
| 200 week MA | $42.8 | 63% below |
EUDA's trend is mixed: it's above one of its five weekly moving averages, and 63% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EUDA on trend strength, trading above more of its moving averages.
EUDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $193.4 | $194.4 | +0.5% |
| 2022 | $194.4 | $36.6 | -81% |
| 2023 | $36.6 | $28.6 | -22% |
| 2024 | $28.6 | $91.4 | +220% |
| 2025 | $91.4 | $49.0 | -46% |
| 2026 YTD | $49.0 | $15.8 | -68% |
EUDA's yearly returns have swung widely, from +220% in 2024 to −81% in 2022. It's down 68% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EUDA on returns for 2026, with the stronger performance.